Articles by Amanda Lanier

Top Trends Economy - DNA, bar graphs

Daiichi Sankyo and Merck’s $22B mega-deal sets a new record

Dec. 19, 2023
By Amanda Lanier
October marked a milestone in biopharma history, with Daiichi Sankyo Co. Ltd. and Merck & Co. Inc.’s $22 billion deal the largest in BioWorld’s records going back to 2014. Tokyo-based Daiichi is granting rights to three of its DXd antibody-drug conjugate candidates for the treatment of multiple solid tumors: ifinatamab deruxtecan, patritumab deruxtecan and raludotatug deruxtecan. The companies will co-develop and co-commercialize the three candidates worldwide, excluding Japan, where Daiichi retains exclusive rights.
Read More
Connecting puzzle pieces
Biopharma deals November 2023

Biopharma deals and M&A remain on track to outpace 2022

Dec. 15, 2023
By Amanda Lanier
Biopharma deals totaled $18.97 billion in November, marking a notable decrease from October’s historic deal value of $44.91 billion. Even still, through the first 11 months of 2023 cumulative deal value reached $194.26 billion, an 18.65% gain over the $163.73 billion recorded in the same period in 2022.
Read More
Stock prices with loss/gain arrows
BioWorld Biopharmaceutical Index (BBI)

Biopharma stocks again on the upswing after rollercoaster year

Dec. 15, 2023
By Amanda Lanier
The BioWorld Biopharmaceutical Index (BBI) made an upward turn to end November with a 4.37% increase for the year. It has been a dynamic year for BBI, which reached a low point at the end of February (down 3.65%) and peaked at the end of August (up 7.87%). In October, BBI ended the month up 0.98% and outperformed both the Nasdaq Biotechnology Index and the Dow Jones Industrial Average.
Read More
Dollar arrows pointing upward
Biopharma financings November 2023

Biopharma funding hits $5.65B in November, with 18% increase YTD

Dec. 12, 2023
By Amanda Lanier
In November, the biopharma industry raised $5.65 billion in total financings. While down from $11.6 billion tracked by BioWorld in October, overall financings are tracking ahead of last year. Biopharma funding has maintained an average of $6.1 billion per month in 2023, surpassing the $5.07 billion monthly average throughout 2022.
Read More

Graphite’s nula-cel perseveres as Kamau emerges from stealth

Dec. 8, 2023
By Amanda Lanier
Following a strategic transaction with Graphite Bio Inc., Kamau Therapeutics is emerging from stealth with sickle cell treatment nulabeglogene autogedtemcel (nula-cel). Kamau received an option to acquire all of Graphite’s genome editing assets, including a platform technology that integrates precision DNA repair using homology directed repair and CRISPR/Cas9, as well as the autologous CRISPR/Cas9 gene corrected CD34+ cell product nula-cel, which offers a potential cure for sickle cell disease derived from the patient's cells.
Read More
Dollar arrows pointing upward
Biopharma financings November 2023

Biopharma funding hits $5.65B in November, with 18% increase YTD

Dec. 8, 2023
By Amanda Lanier
In November, the biopharma industry raised $5.65 billion in total financings. While down from $11.6 billion tracked by BioWorld in October, overall financings are tracking ahead of last year. Biopharma funding has maintained an average of $6.1 billion per month in 2023, surpassing the $5.07 billion monthly average throughout 2022.
Read More